Fig. 3.

Customized RNA-seq. SET_ER/PR assay. For a subset of cases, SET_ER/PR measurements were repeated on the RNA-seq. platform using leftover RNA of the clinically annotated dataset. a The RBA-seq. assay was correlated with the U133A measurements with a good reproducibility of the cut-point (dotted lines). Of note, the cases with ESR1 mutations (black dots) have higher SET_ER/PR values. b Gene expression measurements are plotted against the observed allele frequency of ESR1 mutations (the numbers represent % ESR1 LBD reads with mutation). c, d Kaplan−Meier plots for patients with HR+/HER2− metastatic disease that received endocrine therapy as next treatment